It's not often that the pharmaceutical and medical community are in total agreement. Yet, at this moment in history, the consensus view is that the drugs emerging from the pharma pipeline over the coming years will utterly transform many diseases.
The sheer scale of innovation - standing on the shoulders of some of the greatest scientific discoveries of all time - is astounding. Many of these drugs are biologics and many of them very expensive. What's more, many of these very expensive drugs are being used in combination to deliver extraordinary effectiveness.
But who pays? After all, a drug is only effective if we can afford to pay for it. Healthcare systems were barely coping before the financial crisis of 2008 and many are in decline through lack of funds in this age of austerity. One solution to this global crisis touted by many are the biosimilars; highly similar versions of biopharmaceuticals that have lost exclusivity.
This year, we celebrate a decade of biosimilar use here in Europe, yet the market is very much in its infancy. There are still many unknowns and no one can answer that most pressing of questions - how much will biosimilars save health systems? In Same Difference, we explore that question and ask many more.
With some of the world's biggest biologics teetering on the edge of the patent cliff, biosimilars are big business. Yet, with the market still in its infancy, it's not as easy as you might think to get these cheap biologics to the patients that need them
An ailing NHS needs an injection of innovation to survive. PharmaTimes speaks to the bright thinkers helping to transform the UK's health service
Building reputation is a long-term endeavour yet as pharma moves away from a traditional B2B model to embrace patients, it is becoming a crucial success factor
With predictions of an additional £10bn hole in NHS finances and recession before 2020, the UK government should reassure pharma that a post-Brexit Britain is worth investing in
Pharmaceutical firms might reconsider any mergers or acquisitions that were initially ruled out as too challenging
With moves towards greater transparency gaining momentum, pharma must do all it can to ensure patient safety
As drug development becomes ever more complex, no company can go it alone
New technology could dramatically speed up the clinical development process
Conquer nerves in media interviews with an A-Z of advice for being in the spotlight
An ailing NHS needs an injection of innovation to survive. PharmaTimes speaks to the bright thinkers helping to transform the UK's health service
We live in exciting times of cutting-edge science, truly innovative new medicines and positive changes towards patient-centricity, says Janssen's Jane Griffiths
Since being diagnosed with melanoma, Imogen Cheese has dedicated her life to bringing patients together
